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Epilepsy and GI Disorders
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Abstract
The gastrointestinal system communicates with the brain by way of vagus nerve 
fibers and the gut-brain axis. There is a well-known relationship between autoim-
mune diseases and epileptogenesis, and this may explain the involvement of gut 
microbiota in the course of epilepsy. Many seizures which are described, depending 
the severity and/or duration, as benign or epilepsy may be related and based on 
gastrointestinal origin. Epilepsy and related neurological symptoms may alert the 
clinician to additional life-threatening conditions and complications during the 
course of gastrointestinal system-based chronic disease such as inflammatory bowel 
disease and celiac disease. Since the gut is the only part of inner body exposed to 
environment, novel therapeutic options that target gut microbiata may be promis-
ing in many diseases including epilepsy.
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1. Introduction
The enteric nervous system (ENS), located in the wall of the bowel, is also 
known as the “second brain.” The ENS exhibits a wide similarity to the brain, both 
structurally and functionally. Its neuronal structure is not cemented by collagen 
and Schwann cells but by glial astrocytes of the central nervous system (CNS). It 
has similar complex functions to the brain and contains various neurotransmitters 
[1]. The gastrointestinal system communicates with the brain through vagus nerve 
fibers and the gut-brain axis. The interaction between the CNS and ENS is known 
as the gut-brain axis. This axis is mainly regulated by gut microbiota and related 
neurotransmitters such as 5-hydroxytryptamine (5-HT), also known as serotonin 
[2]. The common features in terms of function between the ENS and the CNS are 
reflected in the context of disorder, in that gastrointestinal dysfunction may be 
seen in neurological diseases, and neurological dysfunction may become evident 
in gastrointestinal disease processes [3]. Painful abdominal cramping, nausea, and 
cyclical vomiting syndrome are related to childhood epilepsy, and also in adults, 
abdominal symptoms are usually associated with idiopathic complex partial or 
secondary generalized seizures [4]. The ketogenic diet has beneficial effects on 
intractable seizures, and has been shown to affect the gut microbiota [5]. The gut 
microbiota and the immune system are interrelated [6]. Gut bacteria balance affects 
the development of autoimmune disorders. For instance, changing the balance of 
Firmicutes and Bacteroidetes in gut microbiota may promote autoimmune disorders 
such as type 1 diabetes mellitus [7]. The balance in the gut microbiota is also linked 
to the pro- and anti-inflammatory immune responses [8]. There is a well-known 
relationship between autoimmune diseases and epileptogenesis, and this may 
explain the involvement of gut microbiota in the course of epilepsy. The incidence 
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of epilepsy differs between developed and developing countries, similarly to the 
differences observed in the gut microbiota [9]. Autoimmune diseases occur when 
the immune system exhibits redundant responses against the tissues of its own 
body. The etiology of autoimmune disease is still unclear, but some potential factors 
such as the environment, genetic predisposition, vaccines, an unbalanced diet, and 
immune disorders have been implicated [10, 11]. A large number of epilepsy cases 
have an autoimmune-related basis, and adjunctive immunotherapy has beneficial 
effects in such cases [12]. Some serum autoantibodies are also epileptogenic, and 
immunomodulatory therapy may attenuate the progression of some epilepsy syn-
dromes [13]. In this context, gut microbiota-targeted therapy may be useful in the 
treatment of certain types of epilepsy syndromes by altering gut-related immunity 
and the gut-brain axis, which is also controlled by neurotransmitters. One case 
report stated that fecal microbiota transplantation cured refractory epilepsy in 
concomitant Crohn’s disease [14].
2. GI disorders could be accompanied by epilepsy or seizures
Electrolyte imbalances resulting from acute or chronic vomiting and diarrhea 
may trigger severe seizures, especially in early childhood. Acute and profound 
electrolyte imbalances may lead to life-threatening neurological deterioration 
and intractable seizures [15]. Electrolyte imbalance and dehydration disrupt the 
regular voltage gradient across cellular membranes and lead to neuronal excit-
ability following impaired neuronal discharge and epileptiform activities. Altered 
plasma osmolality is also substantially involved in the progression of abnormal 
neuronal discharge and disturbed brain metabolism. Electrolyte imbalance-
related seizures are self-limited and do not commonly lead to morphological 
changes in the CNS if treated promptly and adequately. Epileptiform activities 
are commonly seen in patients with sodium abnormalities, hypocalcemia, and 
hypomagnesemia [16]. Seizures are related to electrolyte imbalance that usually 
presents as tonic-clonic type, although focal and other types may also be seen. 
Patients with electrolyte imbalance-related seizure frequently have a concomitant 
history of vomiting and diarrhea [17]. In order to identify the cause of seizures, 
prompt analyses of serum electrolytes and glucose levels should be performed in 
patients with first seizure at any age [18]. Hyponatremia is defined as a sodium 
level of less than 135 mEq/L. Acute hyponatremia (decreased sodium levels within 
a matter of hours) is mainly related to severe neurological deterioration including 
intractable seizures. Cerebral edema and cerebral herniation may be present as 
major life-threatening complications, particularly if serum sodium levels decrease 
to 120 mEq/L within a few hours [19]. Many clinical conditions and drugs may 
be responsible for hyponatremia, but antiepileptic drugs (AED) such as carba-
mazepine (CBZ), oxcarbazepine (OXC), and eslicarbazepine (ESL) should be 
remembered as causative drugs for developing hyponatremia due to inappropriate 
antidiuretic hormone syndrome [20]. Hyponatremia usually occurs as a non-
specific wave slowing in EEG. Other EEG abnormalities include triphasic waves, 
high amplitude delta activity bursts, and central high amplitude delta waves with 
paroxysms. Interestingly, hypernatremia (when sodium levels exceed 145 mEq/L) 
may be seen as a consequence of tonic-clonic seizures. The pathological mechanism 
involved in hypernatremia after seizures depends on muscle contraction-related 
extracellular water depletion. Hypernatremia causes high intracellular osmolality 
of brain cells and shrinkage of the brain. The correction of hypernatremia should 
be gradual in order not to promote severe seizures. Hypocalcemia is defined as a 
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plasma calcium level under 8.5 mg/dL, or an ionized calcium concentration less 
than 4 m/dL. Sodium and potassium abnormalities are more common in gastro-
enteritis, and hypocalcemia may also be seen during the course of gastroenteritis 
[21]. The clinical manifestations of hypocalcemia are related to the degree of 
hypocalcemia and the rate of decrease in serum calcium concentrations. The main 
clinical manifestation of hypocalcemia is neuromuscular excitability and tetany, 
although acute hypocalcemia may result in tonic-clonic, focal motor, and rarely 
absent seizures [22]. The major causes of hypocalcemia are vitamin D deficiency 
and drugs. Antiepileptic drugs (AEDs) such as phenobarbital, phenytoin, carbam-
azepine, and primidone may disrupt the absorption of intestinal calcium and lead 
to hypocalcemic symptoms, including seizures [23]. Hypocalcemia-related seizures 
can be easily treated with calcium therapy, and anticonvulsive therapy is not usu-
ally necessary [24].
Gastrointestinal infections are another cause of the development of epileptiform 
activities. There is a known relationship between diarrhea and seizures, especially 
in early childhood. Convulsion with mild gastroenteritis (CwG) was first reported 
in 1982 by the Japanese researcher Morooka, and is also known as “situation-related 
seizures” [25]. The diagnostic criteria for CwG were defined as follows [26]:
1. The child was previously healthy.
2. Nonfebrile convulsions accompanied by mild gastroenteritis, possible mild 
dehydration, absence of apparent acid intoxication, and electrolyte imbalance.
3. Convulsions mainly occurring during winter, and the gastroenteritis may 
persist for 1–5 days.
4. Convulsions may manifest as single or multiple episodes of generalized tonic-
clonic seizure (GTCS).
5. Normal interictal electroencephalogram (EEG).
6. Normal serum electrolytes, serum glucose, and cerebrospinal fluid (CSF) with 
stool antigen test positive for rotavirus.
7. Favorable prognosis with rare relapse and unimpeded development.
CwG is primarily caused by rotavirus, norovirus, sapovirus, adenovirus, and 
coxsakie virus. Convulsions usually occur between the first and sixth day after 
the initial symptoms of gastroenteritis. The principal agent determined in cases 
of CwG is rotavirus. The mechanisms involved in CwG are still unknown [27]. 
Since CwG only appears in early childhood, it has been hypothesized to be related 
to the immature nervous system, similarly to febrile convulsions. Rotavirus can 
directly reach the central nervous system and cause cerebropathy, encephalitis, 
or convulsions [28]. Children with CwG do not require antiepileptic treatment. 
CWG has a short and benign course, with most episodes ending within 24 hours. 
Acute treatment with antiepileptic should be considered in patients with two or 
more convulsions [29]. Bacterial agents such as Shigella species are also related to 
neurological manifestations, including seizures. The pathophysiological mecha-
nism of Shigella-related seizures has not been elucidated. Shiga toxin availability 
has been shown not to be essential for neurological complication [30]. Cytokines 
and host-immune responses are related to neurological complication during the 
Epilepsy - Advances in Diagnosis and Therapy
4
course of disease [31]. Hyponatremia and hypoglycemia are also another factor 
for developing Shigella-related seizures and other neurological complications. 
Shigella infections are usually serious and life-threatening particularly in the case 
of extraintestinal and systemic involvement in developing countries. Shigella 
dysentery type 1 frequently leads to neurological complications. Appropriate 
treatment of Shigella infections with antibiotics will prevent recurrent seizures and 
neurological deterioration [32].
Abdominal epilepsy (AE) is characterized by a paroxysmal episode of abdomi-
nal pain, various abdominal symptoms, electroencephalogram (EEG) abnormali-
ties, and favorable response to AEDs. AE is commonly seen in childhood although 
there have been reports of adults with AE [33]. Gastrointestinal symptoms associ-
ated with AE include abdominal pain, nausea, and vomiting, and patients may 
also have concomitant neurological symptoms, such as postictal lethargy, drowsi-
ness, headache, blindness, paresthesia, and convulsions [34]. The pathophysiol-
ogy of AE is not well understood, but several hypotheses have been suggested 
including the one which holds that abdominal epilepsy results from abnormal 
brain activity in the temporal lobe involving the amygdala. The amygdala then 
transmits activities to the gastrointestinal tract via direct projections to the dorsal 
motor nucleus of the vagus nerve through which gastrointestinal symptoms are 
felt to localized [35].
There are four diagnostic criteria for AE in the context of noninflammatory, 
neoplastic, metabolic, or anatomic abnormalities.
These are:
a. Otherwise unexplained, paroxysmal gastrointestinal complaints.
b. Symptoms arising from CNS disturbance.
c. An abnormal EEG with findings specific for a seizure disorder.
d. Improvement with anticonvulsant medication.
The most important differential for AE is abdominal migraine. In patients 
presenting with headache, it is very difficult to differentiate AE and abdominal 
migraine because symptoms usually overlap. Duration of the symptoms may be 
used to differentiate the two; being longer in migraine than in AE [36]. EEG is 
usually abnormal in AE and may confirm the diagnosis of AE. There is no recom-
mended special AED therapy for abdominal epilepsy. Most of the patients may 
respond to single-drug therapy [37].
Inflammatory bowel disease: seizures may be seen as a clinical manifestation dur-
ing the course of inflammatory bowel disease (IBD) particularly in severe cases. All 
types of seizures including status epilepticus have been reported. Thromboembolic 
events and various vitamin deficiencies such as thiamine and vitamin B12 are 
mostly responsible for seizures in IBD [38]. In case of seizure, a patient with IBD 
should be evaluated for a cranial thromboembolic event.
Celiac disease is characterized by malabsorption and gastrointestinal symptoms 
due to the intestinal villus injury. Approximately 10% of patients with celiac disease 
exhibit neurological manifestations including seizures [39]. The frequency of celiac 
disease in individuals with epilepsy ranges from 0.78 to 9.1% [40]. It has been sug-
gested that vitamin deficiencies play an important role in the association between 
epilepsy and celiac disease because vitamins have neurotrophic and neuroprotec-
tive effects [41]. Immune mechanisms are also implicated in the pathogenesis of 
epileptic disorders in celiac disease. In support of this hypothesis, anti-Purkinje cell 
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and anti-ganglioside antibodies have been determined in celiac disease patients with 
neurological dysfunction. Most of epileptic patients with celiac disease have been 
cured after adopting a gluten-free diet [42].
3. Gastrointestinal problems associated with antiepileptic drugs
AEDs have a relatively narrow therapeutic index, and their adverse effects can 
impact on any organ or system. Some 10–30% of patients with epilepsy discontinue 
their first prescribed AED due to adverse effects and intolerance [43]. Many AEDs 
cause gastrointestinal side effects. Multi-AEDs in particular may increase the poten-
tial side effects in intractable seizures. The most common AED-related side effects 
are vomiting and nausea [44]. Some important adverse gastrointestinal side effects 
of AEDs are mentioned below.
Valproic acid (VA) may cause gastrointestinal side effects such as nausea, diar-
rhea, abdominal pain, and vomiting. This problem may be seen particularly when 
the initial doses are taken. The meal time ingestion and slow release form of the 
drug will be tolerated by most patients [45]. Acute pancreatitis is also related to VA 
ingestion, and the clinician should suspect this in case of severe abdominal pain 
during VA therapy. Hepatotoxicity is a life-threatening condition related to VA 
therapy. Patients with organic brain disease, treated with several antiepileptic drugs, 
and younger than 2 years old have the highest risk for developing hepatotoxicity 
during VA treatment. Liver function tests, ammonia, and other tests are not reliable 
for assessing VA-related hepatotoxicity. However, clinical symptoms such as vomit-
ing, nausea, anorexia, and lethargy may be an indicator of fatal hepatotoxicity [46].
Benzodiazepines are commonly prescribed drugs particularly in childhood 
epileptic syndromes. Although they exhibit sedation-related adverse effects, 
benzodiazepines are usually well tolerated in the gastrointestinal system and do not 
lead to hepatic damage unless combined with other AEDs [47].
Carbamazepine (CBZ) is well tolerated in the gastrointestinal system, but idio-
syncratic reaction due to CBZ might be related to granulomatous hepatitis, fever, 
and rash [48].
Ethosuximide (ESM) has reversible, adverse gastrointestinal effects, such as 
abdominal discomfort, vomiting, diarrhea, and hiccups, but these can all be 
prevented if ESM is taken after meals [49].
Felbamate and topiramate (TPM) may cause anorexia, thus promoting weight 
loss, and there are reports of fatal hepatotoxicity due to felbamate [50, 51].
4. Conclusions
Gastrointestinal system manifestations may be a milestone of many neurological 
diseases, including epilepsy and benign seizures. Epilepsy and related neurologi-
cal symptoms may alert the clinician to the presence of additional life-threatening 
conditions and complications during the course of gastrointestinal-based chronic 
disease such as inflammatory bowel disease and celiac disease. Since the gut is the 
only part of inner body exposed to environment, novel therapeutic options that 
target gut microbiata may be promising in many diseases including epilepsy.
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